Enrollment is half complete in an ongoing clinical study at Massachusetts General Hospital (MGH) testing whether a PET imaging tracer can…
Articles by Andrea Lobo, PhD
28bio has developed miniature brain models to help evaluate potential treatments that aim to repair myelin, the fatty coating…
The U.S. Food and Drug Administration (FDA) has formally agreed that the design and planned analysis of an upcoming Phase…
More than 5,000 cyclists took part in the 2026 Bike MS: ACC Texas MS 150 event, a two-day fundraising…
The Multiple Sclerosis Association of America (MSAA) will host its 12th annual Improving Lives Benefit on May 7,…
Among people with relapsing forms of multiple sclerosis (MS) and highly active disease, Mavenclad (cladribine) treatment resulted in…
National Football League player Fernando Mendoza and his family are partnering with the National Multiple Sclerosis Society (NMSS) to…
Medthera has launched WalkPort, a supported walking station designed to help people with mobility difficulties, including those with…
Patient enrollment is complete in a Phase 3 trial testing a new formulation of Briumvi (ublituximab-xiiy), TG Therapeutics‘Â …
The portable neuromodulation stimulator (PoNS), a noninvasive device that’s approved to improve walking and balance in people with…
Exposure to higher levels of ground-level ozone may significantly increase the risk that children and teens will develop multiple…
The European Medicines Agency (EMA) has granted PRIME designation to Oculis‘ experimental treatment privosegtor for optic neuritis,…
Quantum Biopharma has officially filed with the U.S. Food and Drug Administration (FDA) for clearance to begin a Phase…
MS Canada is inviting cyclists across the country to take part in its 2026 MS Bike season, a series…
More than 70% of people with multiple sclerosis (MS) receiving outpatient rehabilitation take at least five medications — often…
IMP761, an experimental immunosuppressive therapy being developed by Immutep for multiple sclerosis (MS) and other autoimmune diseases, was…
An experimental therapy designed to eliminate harmful B-cells — key drivers of inflammation in multiple sclerosis (MS) and other…
The National Multiple Sclerosis Society has designated UC Davis Health in California as a new Center for Comprehensive MS…
Innocare Pharma has dosed the first healthy volunteer in a clinical trial in China testing ICP-538, its oral treatment…
People with multiple sclerosis (MS) who experience their first symptoms after age 50 tend to have faster disability progression than…
Immunic Therapeutics has been granted a new patent in Europe covering multiple dosing regimens of its experimental therapy…
People with multiple sclerosis (MS) are about twice as likely to develop restless legs syndrome (RLS) — a…
A researcher at the Walter and Eliza Hall Institute in Australia has received funding from MS Australia to uncover…
A Phase 1 clinical trial testing azercabtagene zapreleucel (azer-cel), TG Therapeutics’ CAR-T-cell therapy, in progressive forms of multiple…
People with multiple sclerosis (MS) have a nearly fivefold increased risk of developing dementia compared with those without the…
Merck and Mayo Clinic have launched a research collaboration to use artificial intelligence (AI) and large-scale clinical data…
Canary Speech and Intermountain Ventures are collaborating to test whether subtle changes in a person’s voice can help identify…
MS Canada is hosting its annual MS Read-a-Thon, a fundraiser encouraging children to turn their reading goals into donations to…
Teva Canada and Novartis Canada formed a partnership to ensure continued access to Mayzent (siponimod) for people in Canada…
People with multiple sclerosis (MS) reported improvements in physical and mental quality of life along with reduced depression after…